Suven Life Sciences shares ended 10% higher after this important announcement

Suven Life said that the primary objective of the study is to assess the safety and tolerability of the SUVN-I6107 by monitoring adverse events, clinical laboratory, vital signs and electrocardiographs.

Leave a Reply

Your email address will not be published. Required fields are marked *